Population genomic screening to detect carriers of rare monogenic variants for medically actionable conditions is supported by substantial evidence of clinical utility and cost effectiveness. Much less evidence supports screening by polygenic risk scores, which do not detect rare variants. Using only polygenic scores in population screening initiatives, while ignoring the detection of higher-risk rare monogenic variants, is ill-advised.
This is a preview of subscription content, log in via an institution to check access.
References
Bean, L. J. H. et al. DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23, 979–988 (2021).
Murray, M. F., Evans, J. P. & Khoury, M. J. DNA-based population screening: potential suitability and important knowledge gaps. JAMA 323, 307–308 (2020).
Lacaze, P. A., Tiller, J. & Winship, I., Group, D. N. A. S. I. Population DNA screening for medically actionable disease risk in adults. Med. J. Aust. 216, 278–280 (2022).
Manchanda, R. et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. BJOG 127, 364–375 (2020).
Zhang, L. et al. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. Genet. Med. 21, 1958–1968 (2019).
Manchanda, R. et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. J. Natl Cancer Inst. 110, 714–725 (2018).
The New York Times. Don’t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns. https://www.nytimes.com/2019/04/16/health/23andme-brca-gene-testing.html (2019).
Ding, Y. et al. Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification. Nat. Genet. 54, 30–39 (2022).
Manchanda, R. et al. Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. J. Med. Genet. 55, 538–545 (2018).
Manickam, K. et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Netw. Open 1, e182140 (2018).
Acknowledgements
The authors thank J. Tiller for her input into this article. P.L. is supported by a National Heart Foundation Future Leader Fellowship (102604) and grants from the Australian Government Department of Health, Medical Research Future Fund, Genomics Health Futures Mission (APP2009024) and National Institutes of Health (1127060). R.M. is funded by the Yorkshire Cancer Research and Eve Appeal into Population testing and has been supported by an NHS Innovation Accelerator (NIA) Fellowship for population testing. R.C.G. is funded by NIH grants: TR003201, HG008685, HL143295, OD026553 and by the Franca Sozzani Fund for Preventive Genomics.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the manuscript.
Corresponding author
Ethics declarations
Competing interests
R.M. declares advisory board membership from Astrazeneca/MSD/EGL/GSK. R.C.G. has received compensation for advising Allelica, Fabric, GenomeWeb, Genomic Life and Verily; and is a co-founder of Genome Medical and Nurture Genomics. P.L. declares no competing interests.
Additional information
Rights and permissions
About this article
Cite this article
Lacaze, P., Manchanda, R. & Green, R.C. Prioritizing the detection of rare pathogenic variants in population screening. Nat Rev Genet 24, 205–206 (2023). https://doi.org/10.1038/s41576-022-00571-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41576-022-00571-9
- Springer Nature Limited